Quick Answer
Axsome Therapeutics, Inc. reported Operating Income Loss of -$166.76 million for the year ending 2025.
- Axsome Therapeutics, Inc. showed an increase of +40.6% in Operating Income Loss from 2024 to 2025.
- This data is from Axsome Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 23, 2026.
- XBRL data for this metric is available from 2014 to 2025 (12 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 12 years of available data (2014 to 2025), Axsome Therapeutics, Inc.'s Operating Income Loss has declined by 2,840.1%.
- Historical annual values: Fiscal year 2025: -$166.76 million | Fiscal year 2024: -$280.56 million | Fiscal year 2023: -$231.83 million | Fiscal year 2022: -$179.80 million | Fiscal year 2021: -$124.71 million | Fiscal year 2020: -$99.14 million | Fiscal year 2019: -$67.25 million | Fiscal year 2018: -$32.85 million | Fiscal year 2017: -$27.16 million | Fiscal year 2016: -$27.54 million | Fiscal year 2015: -$9.20 million | Fiscal year 2014: -$5.67 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: